CellAct Pharma GmbH   Report issue

For profit Phase 2
Founded: Dortmund Germany (2007)
Status: Left NME R&D (2017)

Organization Overview

First Clinical Trial
2011
NCT02094560
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

cap7.1 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1